FBS vs. Serum-Free for AAV Production

The question is not whether serum-free medium is better than FBS for AAV production — in terms of titre, a well-optimised serum-free medium matches FBS. The question is when the regulatory, operational, and quality advantages of serum-free outweigh the adaptation cost. This post gives you a practical decision framework by development phase and intended use.

The honest comparison — FBS vs. serum-free for AAV

Criterion	Optimised FBS (Low Endotoxin)	Serum-Free (Chemically Defined)
AAV titre (optimised)	✅ High — 1×10¹³ – 1×10¹⁴ vg/mL achievable	✅ Equivalent — once adapted
Batch-to-batch consistency	⚠️ FBS lot-dependent — requires lot qualification	✅ Zero compositional variability between batches
Adaptation cost	✅ None — standard HEK293T culture	⚠️ 3–5 passages, potential titre dip during transition
TSE/BSE documentation	⚠️ Required per lot — reviewed in IND/CTA	✅ Not required — no animal components
Adventitious agent risk	⚠️ BVDV and other bovine viruses — requires testing	✅ Eliminated — no animal-derived raw materials
Downstream purification	⚠️ Bovine albumin co-purifies — process impurity	✅ No bovine protein impurities
GMP raw material risk assessment	⚠️ Complex — FBS is highest-risk category	✅ Simplified — ACF components low-risk
Cost per litre of medium	✅ Lower — FBS at 10% is less expensive than full serum-free supplement package at research scale	⚠️ Higher at small scale; comparable at GMP scale

Decision framework by development phase

Early research (proof-of-concept, in vitro studies)

Recommendation: FBS Low Endotoxin

At this stage, speed and simplicity matter more than regulatory compliance. Optimised FBS gives high, reproducible titres without adaptation time. Use Low Endotoxin grade to avoid TLR4-driven titre suppression. Reserve enough of your validated lot to cover the full research phase.

Pre-clinical (in vivo mouse/rat studies, IND-enabling toxicology)

Recommendation: FBS Low Endotoxin with full documentation package, OR start serum-free transition

IND-enabling studies do not formally require serum-free medium, but the FDA and EMA will scrutinise your FBS raw material documentation in the IND/CTA review. If you plan to use the same manufacturing process for the clinical material, starting the serum-free transition at pre-clinical stage allows you to file the IND with serum-free already established — avoiding a major process change between pre-clinical and clinical phases.

IND-enabling / first-in-human

Recommendation: Serum-free chemically defined medium

At this stage, serum-free is strongly preferred by regulators. The FDA and EMA both encourage elimination of animal-derived raw materials in ATMP and gene therapy manufacturing. Batch-to-batch consistency of chemically defined medium simplifies the process consistency data required in the IND Chemistry, Manufacturing and Controls (CMC) section. The TSE/BSE risk assessment burden is eliminated.

Commercial manufacturing (BLA/MAA)

Recommendation: Serum-free chemically defined medium — mandatory in practice

All commercially approved AAV gene therapies (Luxturna, Zolgensma, Hemgenix) are manufactured in serum-free or defined medium. No commercially approved AAV product uses FBS in the final GMP manufacturing process. If you are planning a commercial pathway, starting development in serum-free medium avoids a major process change that would require comparability studies later.

The transition cost — what to budget

The main cost of transitioning from FBS to serum-free is not reagent cost — it is time and production capacity:

• 3–5 passages adaptation: approximately 2–3 weeks for HEK293T
• 1–2 small-scale AAV production runs to confirm titre equivalence before scaling
• Doubling time characterisation in the new medium — required to update your seeding density calculations for target confluency
• Stability data for the finished AAV in serum-free conditions — bovine albumin in FBS-produced AAV provides some stabilisation; serum-free AAV may require formulation buffer optimisation

What to keep from FBS even in serum-free processes

Some FBS use in AAV production cannot be fully eliminated from day one:

• Cell banking: HEK293T master cell banks are typically cryopreserved in FBS-containing medium. Serum-free cell banking is possible but requires optimisation — many programmes maintain FBS-based MCBs while transitioning production to serum-free
• Trypsinisation: standard trypsin is animal-derived. Switch to recombinant trypsin (TrypLE Express, or recombinant porcine trypsin) for ACF compliance